198 related articles for article (PubMed ID: 31621208)
21. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
23. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
24. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
Corbeau A; Kuipers SC; de Boer SM; Horeweg N; Hoogeman MS; Godart J; Nout RA
Radiother Oncol; 2021 Nov; 164():128-137. PubMed ID: 34560187
[TBL] [Abstract][Full Text] [Related]
25. A prospective single-arm study on the relationship between dose-volume parameters of pelvic functional bone marrow and acute hematological toxicities during intensity-modulated radiotherapy with or without concurrent chemotherapy for uterine cervical/endometrial cancer.
Chen H; Zhong Q; Liu Y; Li J; Deng W; Wang J; Zhou S; Yu Z; Huang X; Huang Y; Zhen B; Wei J; Zhang W; Ruan X; Xiao L
Radiat Oncol; 2023 Nov; 18(1):193. PubMed ID: 38012675
[TBL] [Abstract][Full Text] [Related]
26. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study.
Li W; Ma L; Li F; Li K; Zhang Y; Ren H; Bao X; Guo Y; Guo Y; Wang M; Li D; Duan Y; Ma X; Wang Z; Wang Y; Yin R
Radiat Oncol; 2024 Apr; 19(1):46. PubMed ID: 38594678
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.
Li N; Noticewala SS; Williamson CW; Shen H; Sirak I; Tarnawski R; Mahantshetty U; Hoh CK; Moore KL; Mell LK
Radiother Oncol; 2017 May; 123(2):325-330. PubMed ID: 28528206
[TBL] [Abstract][Full Text] [Related]
28. Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation.
Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Trino E; Cassoni P; Arena V; Baccega M; Racca P; Faletti R; Rondi N; Morino M; Ricardi U
Cancer Invest; 2018; 36(5):279-288. PubMed ID: 29953269
[TBL] [Abstract][Full Text] [Related]
29. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
30. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
[TBL] [Abstract][Full Text] [Related]
31. Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies.
Liang Y; Bydder M; Yashar CM; Rose BS; Cornell M; Hoh CK; Lawson JD; Einck J; Saenz C; Fanta P; Mundt AJ; Bydder GM; Mell LK
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):406-14. PubMed ID: 22687195
[TBL] [Abstract][Full Text] [Related]
32. The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer.
Zhang BZ; Li Y; Xu LM; Chai YL; Qu C; Cao YJ; Wang J; Hou HL; Zhang J
Radiat Oncol; 2023 Jan; 18(1):12. PubMed ID: 36658595
[TBL] [Abstract][Full Text] [Related]
33. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
34. Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity.
Marnitz S; Köhler C; Burova E; Wlodarczyk W; Jahn U; Grün A; Budach V; Stromberger C
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e137-43. PubMed ID: 21600704
[TBL] [Abstract][Full Text] [Related]
35. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
[TBL] [Abstract][Full Text] [Related]
36. Incorporating
Franco P; Fiandra C; Arcadipane F; Trino E; Giglioli FR; Ragona R; Ricardi U
BMC Cancer; 2017 Nov; 17(1):710. PubMed ID: 29096619
[TBL] [Abstract][Full Text] [Related]
37. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
38. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
39. Less Than Whole Uterus Irradiation for Locally Advanced Cervical Cancer Maintains Locoregional Control and Decreases Radiation Dose to Bowel.
Kozak MM; Koenig JL; von Eyben R; Kidd EA
Pract Radiat Oncol; 2019 Mar; 9(2):e164-e171. PubMed ID: 30395974
[TBL] [Abstract][Full Text] [Related]
40. Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Carmona R; Pritz J; Bydder M; Gulaya S; Zhu H; Williamson CW; Welch CS; Vaida F; Bydder G; Mell LK
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):155-63. PubMed ID: 25015207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
